Gelonghui October 23 | Joincare (600380.SH) published that, recently, Shenzhen Haibin Pharmaceutical Co. Ltd. (hereinafter referred to as Shenzhen Haibin), the wholly-owned subsidiary of the Company, has received the Notice of Approval of Supplementary Drug Application approved and issued by National Medical Products Administration, that meropenem for injection produced by Shenzhen Haibin has passed the consistency evaluation of quality and curative effect of generic drug.

This product is applicable to infections caused by single or multiple sensitive bacteria to meropenem in adults and children: pneumonia (including hospital acquired pneumonia), urinary tract infection, gynecological infections (such as endometritis and pelvic inflammation), skin soft-tissue infection, meningitis, and septicemia. For empirical therapy, it can be used alone or in combination with antiviral or antifungal agents in adult patients with neutropenia and fever. It can be used alone or in combination with other antimicrobial agents to treat multiple infections. There is no experience in the use of this product in infants with neutropenia or primary and secondary immunodeficiency.

As of the disclosure date of this announcement, the accumulated direct R&D costs of the consistency evaluation of meropenem for injection was about RMB 15.2105 million yuan.